注意欠陥多動性障害(ADHD)治療薬の世界市場:治験レビュー

◆英語タイトル:Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019
◆商品コード:GDT20FB0028
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:796
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥810,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019
Summary

GlobalData’s clinical trial report, “Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H2, 2019″ provides an overview of Attention Deficit Hyperactivity Disorder (ADHD) clinical trials scenario. This report provides top line data relating to the clinical trials on Attention Deficit Hyperactivity Disorder (ADHD)Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 25
In Progress Trials by Phase 26
Clinical Trials by Trial Status 27
Clinical Trials by End Point Status 28
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials 33
Prominent Drugs 34
Latest Clinical Trials News on Attention Deficit Hyperactivity Disorder (ADHD) 35
Nov 11, 2019: Supernus submits New Drug Application for SPN-812 for the treatment of ADHD 35
Nov 05, 2019: Supernus Pharmaceuticals announces data from phase III study of SPN-810 for treatment of Impulsive Aggression (IA) in ADHD patients 35
Nov 04, 2019: Ironshore to present data from a pivotal trial of JORNAY PM (methylphenidate HCl) CII at the 31st Annual International Conference on ADHD 35
Oct 22, 2019: KemPharm presents study highlighting patient-friendly dosing properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting 36
Oct 16, 2019: Ironshore Pharmaceuticals to present data at the 66th Annual AACAP Meeting 36
Oct 04, 2019: Oryzon reveals positive data from anti-aggression drug vafidemstat 37
Sep 23, 2019: ORYZON presents new data on vafidemstat 37
Clinical Trial Profile Snapshots 39
Appendix 821
Abbreviations 821
Definitions 821
Research Methodology 822
Secondary Research 822
About GlobalData 823
Contact Us 823
Source 824

List of Tables
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region, 2019* 8
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 15
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2019* 16
Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 18
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 22
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 23
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 24
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase, 2019* 25
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 26
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 27
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 28
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 29
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 30
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 32
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 33
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 34

List of Figures
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 15
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2019* 16
Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2019* 17
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2019* 21
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 23
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 24
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 25
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 26
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 27
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 28
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 29
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 30
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 31
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 33
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 34
GlobalData Methodology 822

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[注意欠陥多動性障害(ADHD)治療薬の世界市場:治験レビュー]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆